Harnessing the power of the Adipocyte

for treatment of insulin resistance, type 2 diabetes and associated comorbidities

AdipoPharma SAS is a French biotech company committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. The company was created to commercialize the work of its founder, Dr. Vincent Marion PhD, MSc, and Biochemist and researcher at INSERM, the French National Institute for Health and Medical Research. Dr Marion’s team has spent more than a decade identifying therapeutic targets based on the adipocyte’s specific role in the metabolic effects of insulin resistance and diabetes. This work began by the detailed genetic investigation of Alström syndrome, an ultra-rare devastating disease characterized by severe insulin resistance, early-onset type 2 diabetes and associated metabolic dysfunctions.

This led to the development of a detailed analysis of the adipocyte’s complex function, its intrinsic lipid modulating effects and a proprietary targeted approach to treatment.

The result is AdipoPharma's innovative and first-in-class therapeutic peptide “PATAS”, the first Adipeutic drug that will enter clinical trial phase in 2023. This safe and novel therapeutic approach has been shown to restore healthy lipid biosynthesis in the diseased adipocyte leading to reduction of nasty lipids like the ceramides. PATAS is set to be the first anti-diabetic drug to have a significant beneficial effect on insulin resistance, beta cell plaque removal, liver steatosis and fibrosis and ceramides, the leading cause of cardiovascular dysfunction in diabetes.